How to Help Your Patients Find Evenity in Stock: A Provider's Guide

Your patient needs Evenity (romosozumab). They've been assessed, they meet criteria, and the clinical rationale is solid. But in 2026, writing the prescription is just the beginning. Getting Evenity into the patient's arm requires navigating a specialty medication pathway that many practices find frustrating. This guide gives you the practical, workflow-level tools to improve your practice's Evenity access success rate.

Why Evenity Access Is Complex for Practices

Evenity is not a call-in prescription. It's a specialty biologic that must be refrigerated, administered in your office (or another healthcare facility), billed under the medical benefit with J-code J3111 in most cases, and approved by insurance through a prior authorization process. Each of these steps represents a potential access failure point.

Step 1: Standardize Your PA Documentation Template

The most impactful efficiency gain is having a pre-built PA template for your staff that captures all required elements at the time of prescribing. A complete first submission dramatically increases first-pass approval rates and reduces the 2-to-4-week average PA timeline.

Essential elements for every Evenity PA:

DXA T-scores at lumbar spine, total hip, and femoral neck (with date of scan)

Fragility fracture history: site, date, mechanism

Prior osteoporosis treatment history: drug name, dose, duration, reason for discontinuation

FRAX score (if calculated) showing 10-year fracture probability

Cardiovascular history — documenting absence of MI or stroke in preceding 12 months

Calcium and vitamin D supplementation status

Step 2: Enroll the Patient in Amgen SupportPlus Immediately

Do this at the time of prescribing — not after the PA is submitted. Amgen SupportPlus (1-844-AMGEN-11) provides your practice with:

Insurance benefits verification (including medical vs. pharmacy benefit determination)

Prior authorization submission assistance

Specialty pharmacy coordination and shipment to site of care

Patient copay assistance enrollment (Amgen SupportPlus Co-Pay Program)

Appeals support if initial PA is denied

Step 3: Understand Medical vs. Pharmacy Benefit Routing

Evenity is typically administered in a clinical setting, which means it's often billed under the medical benefit (not the pharmacy benefit). In-office administration is billed using J-code J3111. This distinction matters because:

Medicare Part B covers in-office administration (80% after deductible), while Part D covers pharmacy dispensing.

Commercial plans may cover Evenity under the medical benefit with different cost-sharing than the pharmacy benefit.

The patient's out-of-pocket responsibility differs significantly depending on which benefit applies.

Amgen SupportPlus will verify the correct benefit pathway for each patient before you order.

Step 4: Establish a Specialty Pharmacy Relationship

Having an established relationship with 1-2 specialty pharmacies that handle Evenity simplifies the monthly ordering process significantly. Specialty pharmacies ship Evenity in cold-chain packaging directly to your office prior to each patient's appointment. Preferred partners experienced with romosozumab include Accredo, CVS Specialty, Walgreens Specialty, and Optum Specialty.

Step 5: Use medfinder for Patients With Complex Access Issues

For patients experiencing unusual access issues — such as being in a rural area or having a plan that routes through an unusual specialty pharmacy network — medfinder for Providers can help identify pharmacies in the patient's area that can source and coordinate Evenity. medfinder calls pharmacies on your behalf and reports availability, saving your staff significant phone time.

Step 6: Plan the Post-Evenity Transition Before Starting

Evenity's anabolic effect wanes after 12 monthly doses. Clinical guidelines require transition to antiresorptive therapy immediately after completing the course. Write the transition prescription (alendronate, zoledronic acid, or denosumab) before the patient starts Evenity, and include the transition plan in the patient's care plan. This prevents the bone density rebound loss that occurs when Evenity is stopped without follow-on therapy.

When to Consider Alternatives to Evenity

When insurance denials persist after appeals, or when the patient has cardiovascular contraindications, consider teriparatide (Forteo) or abaloparatide (Tymlos) as anabolic alternatives. For a detailed comparison, see our guide to Evenity alternatives.